BR9910553A - Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação - Google Patents

Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação

Info

Publication number
BR9910553A
BR9910553A BR9910553-5A BR9910553A BR9910553A BR 9910553 A BR9910553 A BR 9910553A BR 9910553 A BR9910553 A BR 9910553A BR 9910553 A BR9910553 A BR 9910553A
Authority
BR
Brazil
Prior art keywords
extended release
inflammation
indication
treating
pharmaceutical formulation
Prior art date
Application number
BR9910553-5A
Other languages
English (en)
Inventor
Merrill Seymour Goldenberg
Jian Hua Gu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR9910553A publication Critical patent/BR9910553A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fats And Perfumes (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçãO DE LIBERAçãO PROLONGADA, PROCESSO PARA PRODUçãO DA MESMA, PRODUTO DE LIBERAçãO PROLONGADA, FORMULAçãO FARMACêUTICA, E, PROCESSO PARA TRATAMENTO DE UMA INDICAçãO, DE UM DISTúRBIO E DE UMA INFLAMAçãO" A presente invenção diz respeito a formulações de liberação prolongada usando géis ou partículas tardias de alginato e seus processos.
BR9910553-5A 1998-05-18 1999-05-14 Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação BR9910553A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/080,832 US6432449B1 (en) 1998-05-18 1998-05-18 Biodegradable sustained-release alginate gels
PCT/US1999/010737 WO1999059549A1 (en) 1998-05-18 1999-05-14 Biodegradable sustained-release alginate gels

Publications (1)

Publication Number Publication Date
BR9910553A true BR9910553A (pt) 2001-01-30

Family

ID=22159900

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910553-5A BR9910553A (pt) 1998-05-18 1999-05-14 Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação

Country Status (25)

Country Link
US (2) US6432449B1 (pt)
EP (1) EP1079811B1 (pt)
JP (1) JP2002515419A (pt)
KR (1) KR20010025023A (pt)
CN (1) CN1309556A (pt)
AT (1) ATE343378T1 (pt)
AU (1) AU3993999A (pt)
BG (1) BG65397B1 (pt)
BR (1) BR9910553A (pt)
CA (1) CA2331446C (pt)
CY (1) CY1105944T1 (pt)
DE (1) DE69933763T2 (pt)
DK (1) DK1079811T3 (pt)
EA (1) EA003670B1 (pt)
ES (1) ES2275341T3 (pt)
HU (1) HUP0101895A3 (pt)
IL (1) IL139617A0 (pt)
NO (1) NO20005564L (pt)
NZ (1) NZ507943A (pt)
PL (1) PL199499B1 (pt)
PT (1) PT1079811E (pt)
RS (1) RS49841B (pt)
SK (1) SK16752000A3 (pt)
WO (1) WO1999059549A1 (pt)
ZA (1) ZA200006299B (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007673A1 (en) * 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
KR100426636B1 (ko) * 2001-05-18 2004-04-08 한국과학기술연구원 주사 가능한 젤 상의 조성물 및 그의 제조방법
WO2002100425A1 (en) * 2001-06-11 2002-12-19 Ltt Institute Co., Ltd. Aggregate composition for sustained-release preparation, process for producing the same, and sustained-release preparation containing the same
US20040071780A1 (en) * 2002-01-16 2004-04-15 Lillard James W. PACE-A microspheres for delivery of antigens
US6592852B1 (en) * 2002-04-25 2003-07-15 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Zinc citrate beads in oral compositions
KR100523953B1 (ko) * 2002-08-27 2005-10-25 주식회사 엘지생명과학 천연다당류와 히알루론산의 마이크로비드 및 이의 제조 방법
KR100507545B1 (ko) * 2002-09-03 2005-08-09 주식회사 엘지생명과학 히알루론산 유도체 및 그의 제조방법
JP4459543B2 (ja) * 2003-03-17 2010-04-28 株式会社メドジェル 徐放性ハイドロゲル製剤
US7585496B2 (en) * 2003-11-04 2009-09-08 Lek Pharmaceuticals D.D. Stable pharmaceutical composition granulocyte-colony stimulating factor
CN1319525C (zh) * 2004-09-16 2007-06-06 北京圣医耀科技发展有限责任公司 紫杉醇－海藻酸钠微球血管栓塞剂及其制备
EP1803464A4 (en) * 2004-09-17 2009-09-09 Cellgentech Inc TOPICAL PREPARATION FOR THE TREATMENT OF SKIN DISEASES
EP1799232B1 (en) * 2004-10-12 2015-10-07 FMC Biopolymer AS Self-gelling alginate systems and uses thereof
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8663686B2 (en) * 2005-05-09 2014-03-04 University Of Washington Biodegradable chitosan-PEG compositions and methods of use
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
JP5248492B2 (ja) * 2006-07-14 2013-07-31 エフエムシー バイオポリマー エイエス 低分子量アルギネートを含むヒドロゲルおよびそれから製造されたバイオ構造物
DE102007039871A1 (de) * 2007-08-21 2009-02-26 Friedrich-Baur-Gmbh Weichgewebe-Implantat mit antibakterieller Wirkung
WO2009032158A2 (en) * 2007-08-28 2009-03-12 Fmc Corporation, Inc. Delayed self-gelling alginate systems and uses thereof
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
US20090183503A1 (en) * 2008-01-18 2009-07-23 Alberto Verdesi Exhaust apparatus
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
US9540630B2 (en) * 2008-09-17 2017-01-10 Beta O2 Technologies Ltd. Optimization of alginate encapsulation of islets for transplantation
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
US20130149349A1 (en) * 2010-06-03 2013-06-13 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
CA2804842A1 (en) 2010-07-09 2012-01-12 Board Of Regents Of The University Of Texas System Biodegradable scaffolds
CR20160147A (es) 2011-03-25 2016-08-03 Amgen Inc Formulaciones de anticuerpos
CN102489027B (zh) * 2011-12-12 2014-06-04 山东凯翔生物化工有限公司 一种葡萄糖酸内酯节能浓缩方法及装置
CN103830266A (zh) * 2013-04-24 2014-06-04 杨亚勤 部分氧化海藻酸钠羧甲基化衍生物的制备方法和应用
RU2548777C2 (ru) * 2013-07-09 2015-04-20 Александр Александрович Кролевец Способ получения частиц инкапсулированных жирорастворимой полимерной оболочкой солей металлов, обладающих супрамолекулярными свойствами
CA2954767A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
MX2017000526A (es) 2014-07-14 2017-08-02 Amgen Inc Formulaciones de anticuerpos cristalinos.
EP3334460A4 (en) * 2015-08-13 2019-04-03 Northeastern University BIOMATERIALS FOR ASSOCIATION THERAPY RADIOTHERAPY-CHEMOTHERAPY AGAINST CANCER
EP3501553A1 (en) * 2017-12-21 2019-06-26 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Hydrogel comprising manganese, methods and uses thereof
CN109293138A (zh) * 2018-10-08 2019-02-01 曹布道 一种养殖污水净化处理方法
CN114096237A (zh) 2019-06-21 2022-02-25 阿尔法西格玛有限公司 用于活性成分控释的包含木葡聚糖和醇的凝胶形式的药物组合物
CN112426981B (zh) * 2020-11-30 2021-12-28 西安交通大学 一种金属离子交联水凝胶及制备方法和应用
CN114685778B (zh) * 2020-12-30 2023-10-17 苏州艾博生物科技有限公司 长循环阳离子脂质体的合成方法
CN112843328B (zh) * 2021-02-25 2022-05-13 山东大学 一种具有抑菌作用的鲍鱼壳粉/ZnO复合材料掺杂的智能水凝胶伤口敷料的制备方法
CN114539442A (zh) * 2022-04-02 2022-05-27 青岛海之林生物科技开发有限公司 一种脂溶性藻酸乙酯及其制备方法与应用
CN115850533B (zh) * 2022-09-28 2023-07-21 青岛格诚经纬生物科技有限公司 一种海藻酸材料及其制备方法、应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3640741A (en) * 1970-02-24 1972-02-08 Hollister Inc Composition containing gel
JPS5416979B2 (pt) * 1972-01-08 1979-06-26
US4401456A (en) * 1980-01-09 1983-08-30 The United States Of America As Represented By The Secretary Of Agriculture Controlled release of bioactive materials using alginate gel beads
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4744933A (en) * 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
CA1215922A (en) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US5147861A (en) * 1986-06-30 1992-09-15 Fidia S.P.A. Esters of alginic acid
JPS645460A (en) * 1987-06-29 1989-01-10 Sanei Kagaku Kogyo Kk Production of delaying gelatinous material
CA2121129A1 (en) * 1991-10-29 1993-05-13 Patrick Soon-Shiong Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2275686B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
US5709854A (en) * 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
NZ288997A (en) * 1994-06-24 1999-01-28 Immunex Corp Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate
US5660859A (en) * 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
WO1997015322A1 (en) * 1995-10-25 1997-05-01 The Regents Of The University Of California Methods for restoring or enhancing reproductive function in reproductively impaired hosts
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
WO1998051348A2 (en) * 1997-05-16 1998-11-19 Amgen Inc. Sustained-release delayed gels
GB2339442B (en) * 1998-07-09 2002-06-05 Smith International Downhole tension swivel sub

Also Published As

Publication number Publication date
JP2002515419A (ja) 2002-05-28
PT1079811E (pt) 2007-01-31
EA003670B1 (ru) 2003-08-28
DK1079811T3 (da) 2007-02-26
CN1309556A (zh) 2001-08-22
SK16752000A3 (sk) 2001-09-11
PL344337A1 (en) 2001-11-05
CA2331446A1 (en) 1999-11-25
BG104943A (en) 2001-07-31
US6432449B1 (en) 2002-08-13
EP1079811B1 (en) 2006-10-25
IL139617A0 (en) 2002-02-10
KR20010025023A (ko) 2001-03-26
US20020168406A1 (en) 2002-11-14
PL199499B1 (pl) 2008-09-30
EA200001200A1 (ru) 2001-04-23
BG65397B1 (bg) 2008-06-30
CA2331446C (en) 2004-03-16
HUP0101895A3 (en) 2004-01-28
ATE343378T1 (de) 2006-11-15
WO1999059549A1 (en) 1999-11-25
ZA200006299B (en) 2001-05-30
NO20005564L (no) 2001-01-18
HUP0101895A2 (hu) 2001-10-28
NZ507943A (en) 2003-08-29
DE69933763D1 (de) 2006-12-07
AU3993999A (en) 1999-12-06
ES2275341T3 (es) 2007-06-01
YU69400A (sh) 2003-02-28
NO20005564D0 (no) 2000-11-03
DE69933763T2 (de) 2007-10-04
CY1105944T1 (el) 2011-04-06
EP1079811A1 (en) 2001-03-07
RS49841B (sr) 2008-08-07

Similar Documents

Publication Publication Date Title
BR9910553A (pt) Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação
HUP0203198A2 (hu) Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása
BR9908488A (pt) Composição farmacêutica de topiramato
EE03253B1 (et) (R)-5-karbamoüül-8-fluoro-3-N,N-diasendatud-amino-3,4-dihüdro-2H-1-bensopüraani d, nende valmistamise protsess ja neid sisaldavad ravimkoostised
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
BR9809117A (pt) Composição de gel retardado de liberação prolongada, processo de produzir a mesma, formulação farmacêutica,e , processos de tratamento de uma indicação , de uma doença, e de uma inflamação com uma composição de liberação prolongada
BR0314721A (pt) Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os
BR9916197A (pt) Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
AU6171796A (en) Prodrugs of pharmaceuticals with improved bioavailability
PT93935A (pt) Processo para a preparacao de uma composicao farmaceutica para o tratamento topico de acne vulgar contendo cetoconazol
PH31335A (en) Naphthalamides as central nervous system agent.
ES2135470T3 (es) Composiciones farmaceuticas y metodos que usan ibobutiramida para tratar trastornos de betaglobina.
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
BRPI0114344B8 (pt) composto retinóide, seu uso, sua composição farmacêutica e seu processo de preparação
BR9808427A (pt) Produto, processo de preparação e utilização do mesmo e composição farmacêutica
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
BR0208244A (pt) Pirazolo-e tiazolopirinidinas substituìdas
IL110681A0 (en) Pharmaceutical compositions containing flupirtine for the treatment of neurodegenerative diseases
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR9915436A (pt) Certas caprolactamas substituìdas, composições farmacêuticas contendo as mesmas e seu uso no tratamento de tumores
BR9801985C1 (pt) Composição de gel aplicada na terapêutica da doença de peyronie, de colagenoses e patologias fibróticas
BR0013563A (pt) Preparação farmacêutica sólida, utilização de uma preparação farmacêutica e processo para a produção de uma preparação farmacêutica
BR9713044A (pt) Composto, uso de um composto, processo para sua preparação,e, formulação farmacêutica.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1914 DE 11/09/2007 POR TER SIDO INDEVIDO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1922 DE 06/11/2007.